And, you know, whatever message the Fed was trying to send, I think it's hard to send either a neutral or a dovish message when nearly every question was about inflation
Semaglutide, commonly known as Ozempic or Wegovy, generally leads to weight loss of about 15 to 20 percent of your initial body weight
Many patients experience appetite rebound and modest weight regain after discontinuing GLP-1 therapy, which is expected and not a failure of treatment
Metformin is an oral medication that is gaining some traction, but like Ozempic, it is only FDA-approved to treat type 2 diabetes
Not everyone follows the exact same timeline because factors like baseline metabolism, eating habits, stress, sleep patterns, and individual responsiveness to semaglutide influence how quickly changes occur